Premium
Antibodies against CGRP for prevention of migraine
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
progress in neurology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 12
eISSN - 1931-227X
pISSN - 1367-7543
DOI - 10.1002/pnp.536
Subject(s) - calcitonin gene related peptide , migraine , medicine , calcitonin , monoclonal antibody , adverse effect , antibody , immunology , pharmacology , neuropeptide , receptor
A novel class of agents that block the effects of calcitonin gene‐related peptide (CGRP) may provide a further therapeutic option for people whose migraine has not responded to established treatments or when other preventive treatments are unsuitable due to comorbidities, adverse effects or low adherence. Here the author reviews four monoclonal antibodies that have been licensed or are undergoing regulatory assessment for the prevention of migraine.